MC10029
/ Mayo Clinic
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 17, 2025
A new sort of cells for chimeric antigen receptor T-cell therapies-isolating CD14-CD127+ T cells for chimeric antigen receptor T-cell manufacture.
(PubMed, Cytotherapy)
- "We developed a new two-step isolation method for enriching CD14-CD127+ T cells from PBMCs. This method effectively excluded unwanted B cells, yet maintained the naïve, stem-like central memory and central memory T cells that can produce functional CAR T-cells."
Journal • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor • CD14 • FOXP3 • IL2RA • IL7R
April 02, 2024
Innovative Applications of CAR T-Cell Therapy in Organ Transplant Patients
(ASGCT 2024)
- "The remaining three patients with insufficient B cells, demonstrated CAR T-cells killing activity against antigen-expressing cell line models. This proof-of-concept paves the way for the first-ever application of CAR T-cell therapy in sensitized patients that await life-saving organ transplants."
CAR T-Cell Therapy • Clinical • IO biomarker • Immunology • Transplant Rejection • Transplantation
March 21, 2024
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
(clinicaltrials.gov)
- P1 | N=27 | Recruiting | Sponsor: Mayo Clinic | Not yet recruiting ➔ Recruiting
CAR T-Cell Therapy • Enrollment open • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma
March 02, 2024
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
(clinicaltrials.gov)
- P1 | N=27 | Not yet recruiting | Sponsor: Mayo Clinic | Initiation date: Jan 2024 ➔ Jun 2024
CAR T-Cell Therapy • Trial initiation date • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma
1 to 4
Of
4
Go to page
1